Parathyroid scintigraphy and minimal invasive surgery in parathyroid adenomas

Kulak Burun Bogaz Ihtis Derg. 2015;25(4):205-13. doi: 10.5606/kbbihtisas.2015.33678.

Abstract

Objectives: This study aims to identify the diagnostic capacity of the technetium 99m sestamibi scintigraphy with single photon emission computed tomography for localizing parathyroid pathologies.

Patients and methods: Data of 13 patients (4 males, 9 females; mean age 49.23 years; range 27 to 63 years) who had minimally invasive parathyroidectomy due to primary hyperparathyroidism at the Haseki Training and Research Hospital Ear-Nose-Throat clinic between January 2013 and December 2013 were retrospectively analyzed. Two patients were excluded due to incomplete documentation.

Results: Mean preoperative parathyroid hormone and calcium levels were 284.36 (134-1,083 pg/mL) and 11.9 (10.7-13.5 mg/dL), respectively. The operation was deemed adequate if intraoperative parathyroid hormone dropped by 50% from the preoperative level or frozen section analysis showed hypercellular gland or adenoma. Only sestamibi scintigraphy results were consistent with focal exploration findings in all patients. Focal exploration and parathyroid adenoma excision via minimally invasive parathyroidectomy were successfully carried out in 10 patients with single adenoma confirmed by sestamibi.

Conclusion: Technetium 99m sestamibi scintigraphy with single photon emission computed tomography and frozen section analysis may provide more meaningful information and be more advantageous compared to other preoperative localization techniques.

MeSH terms

  • Adenoma / diagnostic imaging*
  • Adenoma / surgery
  • Adult
  • Female
  • Humans
  • Male
  • Middle Aged
  • Minimally Invasive Surgical Procedures / methods*
  • Parathyroid Neoplasms / diagnostic imaging*
  • Parathyroid Neoplasms / surgery
  • Parathyroidectomy / methods*
  • Radiopharmaceuticals
  • Retrospective Studies
  • Technetium Tc 99m Sestamibi
  • Tomography, Emission-Computed, Single-Photon / methods*

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi